Comparative Pharmacology
Head-to-head clinical analysis: CARBAGLU versus GLYCEROL PHENYLBUTYRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBAGLU versus GLYCEROL PHENYLBUTYRATE.
CARBAGLU vs GLYCEROL PHENYLBUTYRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbaglu (carbonic anhydrase inhibitor) reduces intraocular pressure by inhibiting carbonic anhydrase in the ciliary processes, thereby decreasing aqueous humor secretion.
Glycerol phenylbutyrate is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This compound is excreted by the kidneys, providing an alternative pathway for waste nitrogen excretion in patients with urea cycle disorders.
100 mg/kg (up to 200 mg/kg) intravenous infusion over 90 minutes, followed by 100 mg/kg/day continuous intravenous infusion; maintenance: 100 mg/kg/day oral divided into 2-4 doses, not to exceed 20 g/day.
450-600 mg/m2/day orally in three divided doses, rounded to the nearest 100 mg; maximum 20 g/day.
None Documented
None Documented
Clinical Note
moderateGlycerol phenylbutyrate + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Glycerol phenylbutyrate."
Clinical Note
moderateGlycerol phenylbutyrate + Atorvastatin
"The risk or severity of adverse effects can be increased when Glycerol phenylbutyrate is combined with Atorvastatin."
Clinical Note
moderatePrednisolone + Glycerol phenylbutyrate
"The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Prednisolone."
Clinical Note
moderateTerminal half-life approximately 5.8 hours in adults; prolonged in hepatic impairment (up to 10 hours).
0.8–1 hours (glycerol phenylbutyrate); 1.2–1.5 hours (phenylacetate); clinical context: short half-life requires thrice-daily dosing
Primarily renal excretion (97% unchanged) with minimal biliary/fecal elimination (<3%).
Renal: >90% as phenylbutyrate metabolites (mainly phenylacetylglutamine) within 24 hours; fecal: <1%
Category C
Category C
Ammonia Detoxicant
Ammonia Detoxicant
Dexamethasone + Glycerol phenylbutyrate
"The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Dexamethasone."